Dr. Judith Klimovsky, M.D.,
HOUSTON, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Judith Klimovsky, M.D., to its board of directors effective December 20, 2018. Dr. Klimovsky currently serves as the Executive Vice President & Chief Development Officer of Genmab, an international biotechnology company developing antibody therapeutics for cancer, where she leads the company’s product development efforts. She is replacing Frank McGuyer, who resigned from the board effective December 20, 2018. Mr. McGuyer served as a member of the board for nine years.
“We are pleased to welcome Judith to our board of directors; she brings to the board extensive leadership experience in drug development—particularly in our key focus areas of oncology and hematology. We’re looking forward to working closely with Judith as we continue to advance and expand our pipeline of controllable cell immunotherapies,” said Bellicum’s President & CEO Rick Fair. “We would also like to acknowledge and thank Frank McGuyer, who is stepping down as a director, for his many years of distinguished service to our Company.”
Dr. Klimovsky has more than 15 years of experience in product strategy, drug development and medical affairs for the biotech and pharmaceutical industry. Prior to joining Genmab, she held successively senior positions at Bristol-Myers Squibb, Merck and Novartis and led or contributed to the clinical development of key cancer drugs, including ixabepilone (BMS), MEK162, LGX818 and Afinitor (Novartis). Previously, Dr. Klimovsky served in various hematology clinical practice positions in Buenos Aires, Argentina. Dr. Klimovsky earned her M.D. from the Buenos Aires University School of Medicine.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-celTM, is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information can be found at www.bellicum.com.
